Anticoagulation for Long COVID: Exploring the Microclot Hypothesis and Treatment Options

The concept of utilizing anticoagulation for Long COVID is rooted in the pioneering research of Professor Resia Pretorius from Stellenbosch University in South Africa and Professor Douglas Kell from the University of Liverpool. Early in the pandemic, their collaborative studies identified that acute COVID-19 was not merely a respiratory illness, but fundamentally a vascular and thrombotic disease. They discovered that the persistent presence of the SARS-CoV-2 spike protein triggers a profound dysregulation of the body's coagulation system, leading to the formation of anomalous, microscopic blood clots. These microclots are highly resistant to the body's natural breakdown processes, allowing them to circulate and persist for months or even years after the initial viral infection has cleared.

This persistent hypercoagulability provides a direct physiological explanation for the wide array of debilitating Long COVID symptoms. When these microscopic clots become lodged in the tiny capillaries of the brain, lungs, and muscles, they physically obstruct the smooth flow of red blood cells. This obstruction creates a state of chronic tissue hypoxia, meaning the body's cells are starved of the oxygen and nutrients required for normal function. By understanding this mechanism, researchers hypothesized that aggressive, targeted anticoagulation therapy could help dissolve these persistent clots, alleviate the hypoxic burden, and significantly improve the quality of life for patients suffering from Long COVID.

In a healthy physiological state, blood clotting is a carefully balanced process designed to stop bleeding after an injury, followed by a natural degradation process once the tissue has healed. However, the clotting pathology observed in Long COVID is highly abnormal and complex. Standard, single-agent blood thinners, which are typically prescribed for conditions like deep vein thrombosis (DVT) or atrial fibrillation, have often proven insufficient for resolving the deep-seated microvascular issues seen in Long COVID patients. The microclots associated with this condition are not only structurally different from normal clots, but they are also accompanied by severe platelet hyperactivation and widespread damage to the blood vessel linings (endothelialitis).

Because the pathology involves multiple overlapping systems—the coagulation cascade, hyperactive platelets, and damaged endothelium—researchers like Dr. Jaco Laubscher began exploring a more comprehensive approach known as triple anticoagulation therapy. This aggressive regimen combines a direct oral anticoagulant with two different antiplatelet medications to simultaneously block new clot formation, calm hyperactive platelets, and provide the vascular system an opportunity to heal. While this approach has shown promise in early observational studies, it represents a significant departure from standard medical protocols and carries substantial risks that require careful medical supervision.

For individuals living with Long COVID, the microclot hypothesis offers immense validation. For years, many patients have been told that their profound fatigue, cognitive dysfunction, and shortness of breath were simply manifestations of anxiety or deconditioning. The physical visualization of these microclots under specialized fluorescence microscopy provides undeniable proof that Long COVID is a physiological, organic disease driven by measurable vascular pathology. This biological validation is a crucial step in shifting the medical narrative away from psychological dismissal and toward concrete, physiological treatment strategies.

Furthermore, understanding the role of microclots helps explain the interconnected nature of Long COVID with other complex chronic conditions. The vascular damage and tissue hypoxia caused by these clots can trigger secondary issues, such as dysautonomia and mast cell activation syndrome (MCAS), by creating a chronic state of systemic stress and inflammation. By targeting the root cause of the hypercoagulability, anticoagulation therapies aim to interrupt this vicious cycle of inflammation and clotting, offering hope for comprehensive symptom relief. For a deeper understanding of how these conditions overlap, you can read our Understanding Long COVID: Causes, Symptoms, and What the Science Says guide.

To understand how anticoagulation works for Long COVID, it is essential to explore the intricate biology of how these abnormal clots form. In a normal coagulation process, a soluble plasma protein called fibrinogen is converted into a spaghetti-like web of fibrin to bind a clot together and stop bleeding. However, research by Pretorius and Kell has demonstrated that the SARS-CoV-2 spike protein—specifically the S1 subunit—directly interacts with fibrinogen in the bloodstream. When the spike protein binds to fibrinogen, it causes the protein to misfold and polymerize into a highly dense, rigid, and anomalous structure that is rich in beta-sheets. This structural change is the foundational step in the Long COVID clotting cascade.

These misfolded, amyloid-like structures are vastly different from normal, healthy blood clots. Kell and Pretorius coined the term "fibrinaloids" to describe these abnormal fibrin microclots. Unlike normal clots, which are relatively loose and easily degraded by the body, fibrinaloids are dense, dark, and highly resistant to natural breakdown. Furthermore, these microclots act as circulating "garbage bags," heavily entrapping various inflammatory molecules, including von Willebrand Factor, C-reactive protein, and plasminogen, which continuously fuel systemic inflammation as they travel through the bloodstream.

The persistence of these fibrinaloid microclots is primarily due to a phenomenon known as fibrinolytic shutdown. In a healthy body, an enzyme called plasmin is responsible for breaking down (lysing) blood clots once they are no longer needed. However, the amyloid nature of the Long COVID microclots makes them highly resistant to plasmin degradation. Additionally, studies have shown that these microclots heavily entrap Alpha-2 antiplasmin, a molecule that actively inhibits the clot-busting action of plasmin. Because the body's natural fibrinolytic system is effectively shut down, the microclots persist in the circulation for months or years, creating a chronic state of hypercoagulability.

This fibrinolytic shutdown explains why standard blood tests, such as the D-dimer test, frequently return normal results in Long COVID patients. The D-dimer test measures the breakdown products of a dissolving clot. Because the fibrinaloid microclots are resistant to breakdown, they do not release D-dimers into the bloodstream, resulting in a "normal" test result despite the presence of widespread, systemic micro-clotting. This diagnostic blind spot has been a major hurdle in recognizing and treating the vascular pathology of Long COVID.

The biological chaos of Long COVID extends beyond the plasma proteins to include the cellular components of the blood, specifically the platelets and the endothelium (the inner lining of the blood vessels). The continuous circulation of the viral spike protein, inflammatory cytokines, and abrasive microclots causes severe damage to the delicate endothelial cells. This condition, known as endothelialitis, strips away the protective layer of the blood vessels, exposing underlying tissues and triggering a massive immune and coagulation response.

In response to this endothelial damage, blood platelets become heavily hyperactivated. These "angry platelets" clump together and bind to the circulating microclots, forming large, complex aggregates. This platelet hyperactivation drives a vicious, continuous cycle: the damaged endothelium activates the platelets, the active platelets release more inflammatory chemicals that fuel microclot formation, and the resulting microclots cause further damage to the endothelium. Anticoagulation and antiplatelet therapies aim to break this cycle by calming the platelets and preventing the formation of new fibrin webs.

The ultimate consequence of this widespread microvascular clotting is severe tissue hypoxia. Because the microclots are large enough to physically obstruct the smallest microcapillaries, they block the smooth flow of oxygen-rich red blood cells to vital organs. This cellular oxygen starvation provides a direct biological explanation for the hallmark symptoms of Long COVID. When the brain is deprived of oxygen, patients experience severe cognitive dysfunction, commonly referred to as brain fog. When the muscles are deprived of oxygen, patients experience profound, debilitating physical fatigue. You can explore more about cognitive symptoms in our guide, What Is “Brain Fog” and Cognitive Dysfunction in Long COVID?.

Furthermore, this hypoxic state is deeply connected to post-exertional malaise (PEM), the severe symptom crashes patients experience after physical or cognitive exertion. Dr. Kell has hypothesized that when a patient exerts themselves, the heart pumps harder, forcing blood through these partially blocked, hypoxic vessels. The sudden rush of oxygen-rich blood into previously oxygen-deprived tissue creates a massive localized surge of free radicals and oxidative stress, known as an ischemic reperfusion injury. This cellular damage is believed to be the physiological trigger for the debilitating PEM crashes. For a deeper dive into this mechanism, read our article on Post-Exertional Malaise and Long COVID: Why Crashing After Activity Happens.

The clinical evidence supporting the use of anticoagulation for Long COVID is currently rooted in observational studies and clinical case series, primarily emerging from South Africa. Dr. Jaco Laubscher, working in collaboration with Professor Resia Pretorius, pioneered the clinical application of the microclot hypothesis by treating Long COVID patients with a highly aggressive, off-label regimen known as triple anticoagulation therapy. Their initial goal was to address the "trio of chaos" observed in these patients: the persistent clotting cascade, severe platelet hyperactivation, and widespread endothelial damage.

In an early observational analysis, researchers tracked 24 Long COVID patients who were treated with this triple therapy regimen. The clinical outcomes were highly encouraging. Following the treatment protocol, specialized fluorescence microscopy revealed that the microclotting and platelet hyperactivation had completely resolved in all 24 patients. More importantly, the patients reported a return to their pre-COVID health levels, with a significant reduction in debilitating fatigue, brain fog, and shortness of breath. This early success provided the first clinical indication that targeting the coagulation system could yield profound symptom relief.

Building on the initial 24-patient study, the South African research team published a more extensive pre-print study detailing the outcomes of 91 Long COVID patients treated at Dr. Laubscher's clinic. This larger cohort provided a more comprehensive view of the therapy's potential efficacy across a broader range of symptoms. The researchers meticulously tracked nine main Long COVID symptoms: cognitive dysfunction, fatigue, shortness of breath, joint pain, depression and anxiety, sleep disturbance, palpitations, chest pain, and digestive issues.

The results of the 91-patient cohort mirrored the early observational success. Following the completion of the triple anticoagulation regimen, fluorescence microscopy again demonstrated a marked visual reduction in the presence of amyloid microclots and hyperactivated platelets. Clinically, the vast majority of the patients reported significant, life-changing symptom relief across all nine tracked categories. In subsequent medical interviews, Dr. Laubscher claimed to have treated over 370 Long COVID patients with this protocol, consistently observing high rates of symptom resolution and functional recovery.

Because standard coagulation tests like the D-dimer often fail to detect Long COVID microclots, researchers have turned to advanced viscoelastic testing (VET), specifically Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM). These point-of-care tests measure the real-time kinetic profile of a blood clot, from its initial formation to its eventual breakdown. Studies utilizing TEG have consistently shown that Long COVID patients exhibit a profound state of hypercoagulability and severe fibrinolytic shutdown, meaning their blood clots too easily and fails to break down naturally.

Recent prospective observational studies have further validated the use of these tools. A 2024 study published in Diagnostics utilized ROTEM to track hospitalized COVID-19 patients and found that those displaying a hypercoagulable profile at discharge were significantly more likely to experience Long COVID symptoms months later. Furthermore, the persistence of these VET-detected procoagulant states strongly correlates with the persistence of structural lung damage and reduced oxygen diffusion capacity. These advanced diagnostic tools are now being used not only to prove the existence of the clotting pathology but also to guide and monitor the efficacy of active anticoagulant treatments.

Despite the highly promising observational data and the compelling biological rationale, the broader medical and scientific community has issued strong warnings regarding the widespread adoption of triple anticoagulation therapy. The primary concern is that, to date, there are no large-scale, peer-reviewed, randomized placebo-controlled clinical trials (RCTs) validating this specific protocol for Long COVID. Observational studies, while valuable for generating hypotheses, are subject to significant biases, including the placebo effect and patient selection bias.

Hematology experts and health watchdogs emphasize that while microclots are clearly a biomarker for Long COVID, it is not yet definitively proven in controlled settings that they are the sole root cause of the disease, or that the benefits of aggressive anticoagulation outweigh the severe bleeding risks. Mainstream medical authorities, including the NIH and NICE, caution that the microclot hypothesis requires further rigorous peer review and large-scale RCTs before off-label, aggressive anticoagulant regimens can be recommended as a standard of care. Until these trials are completed, the treatment remains highly experimental.

The specific protocol utilized by Dr. Laubscher in the South African observational studies is an aggressive, multi-targeted approach known as triple anticoagulation therapy. This regimen is designed to simultaneously address the different facets of the Long COVID clotting pathology by combining a direct oral anticoagulant (DOAC) with dual antiplatelet therapy (DAPT). It is critical to understand that this is an off-label use of these medications, and the dosages and combinations are specifically tailored to combat the severe hypercoagulability observed in Long COVID.

The standard daily regimen typically includes four components. First, Clopidogrel (typically 75 mg once a day) is used as the primary antiplatelet agent to prevent platelets from clumping together. Second, Aspirin (typically 75 mg once a day) is added as a secondary antiplatelet to further suppress platelet hyperactivation. Third, Apixaban (typically 5 mg twice a day), a direct oral anticoagulant, is used to inhibit the coagulation cascade and prevent the formation of new fibrin webs. Finally, a proton pump inhibitor (PPI), such as Pantoprazole (40 mg/day), is strictly required to protect the stomach lining and prevent severe gastrointestinal bleeding and ulcers caused by the aggressive blood thinners.

The duration of the triple anticoagulation therapy is highly variable and depends significantly on the chronicity and severity of the patient's Long COVID symptoms. According to the clinical reports from the South African cohort, the treatment is not a quick fix; it requires a sustained, multi-month commitment to allow the body to slowly clear the persistent microclots and heal the damaged endothelium. Patients are typically monitored closely throughout the entire duration of the therapy to assess symptom improvement and manage side effects.

For patients who have been suffering from Long COVID for less than six months (often referred to as 'short' Long COVID), the treatment duration generally lasts between 2 to 4 months. However, for patients with chronic Long COVID who have been ill for more than six months, the required treatment duration is often extended to 4 to 6 months, or sometimes even longer. The therapy is typically initiated with careful titration, and the discontinuation of the medications must be managed slowly and under strict medical supervision to prevent a rebound effect of hypercoagulability and symptom relapse.

Because of the severe risks associated with combining three powerful blood-thinning medications, continuous and rigorous medical monitoring is an absolute requirement for this therapy. Standard blood tests, such as complete blood counts (CBC) and basic metabolic panels, are routinely performed to monitor for hidden bleeding, anemia, and kidney or liver function changes. Patients are also closely monitored for any clinical signs of hemorrhaging, such as excessive bruising, nosebleeds, or blood in the stool or urine.

In specialized clinics, the administration and titration of the triple therapy are often guided by advanced viscoelastic testing, such as TEG or ROTEM. By regularly measuring the real-time kinetic profile of the patient's blood clots, clinicians can objectively assess whether the hypercoagulability is resolving and whether the fibrinolytic shutdown is reversing. This personalized, data-driven approach allows healthcare providers to adjust the dosages of the anticoagulants and antiplatelets based on the patient's specific physiological response, thereby maximizing the therapeutic benefit while attempting to minimize the severe bleeding risks.

The most critical safety consideration regarding triple anticoagulation therapy is the profound and severe risk of major bleeding events. Combining two antiplatelet medications (Clopidogrel and Aspirin) with a direct oral anticoagulant (Apixaban) intentionally and drastically impairs the body's ability to form blood clots. While this is the desired effect for clearing Long COVID microclots, it simultaneously removes the body's primary defense mechanism against internal and external bleeding. This makes the patient highly vulnerable to life-threatening hemorrhages from even minor injuries or spontaneous internal bleeds.

Medical experts and hematologists have issued strong warnings about the dangers of this protocol. The risks include severe gastrointestinal bleeding, prolonged nosebleeds, bleeding into the joints, and, most critically, intracranial hemorrhaging (bleeding in the brain), which can be fatal or cause permanent neurological damage. In his clinical reports, Dr. Laubscher noted that while major bleeding events were rare in his monitored cohort (two out of 373 patients, with one requiring hospitalization), the inherent risks of the medications cannot be understated. Any patient considering this therapy must be fully informed of these severe, potentially life-threatening risks.

Beyond the risk of major hemorrhages, patients undergoing triple anticoagulation therapy frequently experience a range of highly disruptive, though less immediately life-threatening, side effects. The most common complication is severe, widespread bruising. Because the blood is so thin, even minor bumps or everyday physical activities can result in large, painful hematomas under the skin. Patients must take extreme precautions to avoid falls, cuts, and physical trauma while on the medication regimen.

Gastrointestinal complications are also a major concern. The combination of Aspirin and Clopidogrel is notoriously harsh on the stomach lining and can rapidly cause gastric ulcers and bleeding. This is why the strict, daily use of a proton pump inhibitor (PPI) is a non-negotiable component of the therapy. Even with a PPI, patients may experience significant stomach pain, acid reflux, and nausea. If a patient notices dark, tarry stools or vomits material that looks like coffee grounds, it is a medical emergency indicating a severe gastrointestinal bleed that requires immediate hospitalization.

Due to the desperation caused by the debilitating symptoms of Long COVID, a concerning trend of "medical tourism" has emerged. Patients are traveling overseas to private, unregulated clinics to receive expensive, off-label treatments, including triple anticoagulation and blood-washing procedures like HELP apheresis. Health watchdogs and medical journals, including the BMJ, have strongly warned against this practice. Patients are often spending their life savings on unproven therapies and returning home with severe complications and no access to long-term follow-up care.

It is critically important to understand that attempting to replicate this triple therapy regimen without expert, continuous medical supervision is highly dangerous and irresponsible. The precise dosing, the requirement for advanced viscoelastic monitoring, and the immediate need for medical intervention in the event of a bleed mean that this protocol cannot be safely managed by a primary care physician unfamiliar with complex hematology, nor can it be self-administered. The therapy must only be undertaken under the direct care of a specialist who is fully equipped to manage the severe coagulation risks.

Discussing emerging, off-label treatments like triple anticoagulation therapy with your healthcare provider can be a challenging process. Because the microclot hypothesis is still relatively new and lacks large-scale randomized controlled trials, many primary care physicians and even specialists may not be fully aware of the latest research. To have a productive conversation, it is crucial to arrive at your appointment well-prepared. Bring printed copies of the key peer-reviewed studies, such as the Biochemical Journal paper by Kell and Pretorius and the clinical pre-prints detailing the observational cohort outcomes.

When presenting this information, focus on how the research aligns with your specific, documented symptoms, particularly severe fatigue, brain fog, and post-exertional malaise. Frame the conversation collaboratively, acknowledging that while the treatment is experimental, the biological rationale for vascular and endothelial damage in Long COVID is strong. Ask your provider if they would be willing to review the literature with you or refer you to a hematologist or a specialized Long COVID clinic that is actively engaging with the latest coagulation research.

A critical part of the conversation should focus on diagnostics. Explain to your provider that standard coagulation panels, such as the D-dimer test, often fail to capture the specific amyloid microclotting and fibrinolytic shutdown associated with Long COVID. Ask if it is possible to order advanced viscoelastic testing, such as Thromboelastography (TEG) or Rotational Thromboelastometry (ROTEM). While these tests are typically used in surgical or trauma settings, they are becoming increasingly recognized as valuable tools for identifying the hypercoagulable phenotype in Long COVID patients.

If your provider is unfamiliar with TEG or ROTEM, provide them with the recent literature demonstrating their utility in tracking Long COVID coagulopathy. Even if your provider is not comfortable prescribing aggressive triple anticoagulation therapy, obtaining objective evidence of hypercoagulability through viscoelastic testing can validate your symptoms and open the door to safer, more conservative management strategies. It also provides a baseline metric to track your progress over time.

Given the severe bleeding risks associated with prescription triple anticoagulation therapy, many healthcare providers will understandably be hesitant to prescribe it outside of a clinical trial. If this is the case, it is highly productive to pivot the conversation toward safer, evidence-based alternatives that target the same microclot pathology. One of the most promising alternatives currently being researched by Professor Pretorius's team is Nattokinase, a natural enzyme derived from fermented soybeans.

Recent in vitro studies have shown that Nattokinase can directly attack and degrade the rigid beta-sheet structures of the amyloid fibrinaloids, effectively dismantling the microclots piece by piece. Because Nattokinase works by breaking down existing clots rather than aggressively blocking the formation of new ones, it carries a significantly lower risk of severe bleeding compared to prescription anticoagulants. Discuss with your provider whether incorporating a high-quality Nattokinase supplement into your regimen is a safe and appropriate option for your specific health profile. For a comprehensive overview of this supplement, read our guide: Can Nattokinase Help Clear Microclots in Long COVID and ME/CFS?.

The discovery of fibrin amyloid microclots and the subsequent exploration of anticoagulation therapies represent one of the most significant breakthroughs in Long COVID research to date. For millions of patients suffering from debilitating fatigue, severe brain fog, and persistent post-exertional malaise, the microclot hypothesis provides profound biological validation and a tangible target for treatment. The early observational successes of triple anticoagulation therapy offer genuine hope that the complex vascular and endothelial damage caused by the SARS-CoV-2 virus can be reversed, allowing patients to reclaim their health and quality of life.

However, this hope must be carefully balanced with strict clinical caution. The aggressive combination of multiple blood-thinning medications carries severe, potentially life-threatening risks of hemorrhage and gastrointestinal bleeding. Until large-scale, randomized controlled trials definitively prove the safety and efficacy of this specific protocol, it remains a highly experimental approach that must only be undertaken under the direct, continuous supervision of specialized medical professionals. Patients must critically weigh the potential benefits against the significant dangers of unsupervised, off-label treatments.

The landscape of Long COVID research is evolving rapidly, and the medical community is actively working to bridge the gap between observational findings and rigorous clinical standards. Ongoing studies are focused on standardizing diagnostic tools, such as viscoelastic testing and fluorescence microscopy, to make them more accessible to mainstream clinics. Furthermore, researchers are continuously exploring safer, more targeted therapeutic alternatives, including advanced enzymes like Nattokinase and novel anti-inflammatory agents, that can dismantle microclots without the severe bleeding risks associated with traditional anticoagulants.

As our understanding of the interconnected nature of Long COVID, ME/CFS, and dysautonomia deepens, treatment approaches will become increasingly personalized and multidisciplinary. By continuing to advocate for rigorous scientific research and compassionate, evidence-based clinical care, we move closer to a future where post-acute infection syndromes are no longer invisible illnesses, but treatable, manageable conditions. If you are struggling with cognitive symptoms related to Long COVID, you may also want to explore our resources on Can CurcumaSorb Mind Help Clear Brain Fog in Long COVID and ME/CFS? and Can Memory Pro Help Lift Brain Fog in Long COVID and ME/CFS?.

Navigating the complexities of Long COVID and emerging treatments can be an overwhelming and isolating experience. It is crucial to remember that you do not have to manage this journey alone. Building a supportive healthcare team that listens to your experiences, validates your symptoms, and stays informed on the latest scientific research is essential for your long-term recovery and well-being. Always consult with your primary care physician or a qualified specialist before starting, stopping, or changing any medication or supplement regimen, especially those involving blood coagulation.

At RTHM, we are dedicated to providing compassionate, science-backed care for individuals living with complex chronic conditions like Long COVID, ME/CFS, and POTS. Our clinical team is deeply engaged with the latest research, including the microclot hypothesis, and we are committed to helping you navigate your treatment options safely and effectively. To learn more about our comprehensive, personalized approach to chronic illness management, explore RTHM's clinical services and discover how we can support your path forward.